NasalOxy®: A NEXTGENERATION LOW-FLOW OXYGEN THERAPY INTERFACE FOR ENHANCED OXYGENATION AND PATIENT COMFORT

INTRODUCTION

Low-flow oxygen therapy remains a cornerstone in the management of acute and chronic respiratory
diseases, including COPD, pneumonia, and chronic respiratory insufficiency, where effective and consistent oxygen delivery is essential. However, conventional oxygen delivery systems, particularly nasal cannulas, are frequently associated with limitations in oxygenation efficiency, mucosal irritation, and reduced patient adherence [1,2].

CNSAC NasalOxy® is a patented nasal/oral oxygen delivery interface designed to address these challenges through a prong-free architecture and a novel oxygen distribution mechanism. This white paper evaluates the clinical rationale, technological innovation, and therapeutic relevance of NasalOxy®.

OVERVIEW

Oxygen therapy is a fundamental intervention for patients with hypoxemia and respiratory insufficiency and is strongly recommended across international clinical guidelines [1]. Its effectiveness depends not only on oxygen flow rate but also on the efficiency of the oxygen delivery device and patient adherence.

Conventional nasal cannulas remain widely used due to their simplicity; however, oxygen delivery efficiency
may be affected by variability in breathing patterns and dilution of oxygen with ambient air [2]. Prolonged
use is also associated with mucosal dryness and irritation, risk of epistaxis, and reduced patient tolerance over time.

Mitigation focus of this paper

This document examines how CNSAC NasalOxy®, a patented nasal/oral oxygen delivery interface, addresses the limitations of conventional systems by generating a localized oxygen-enriched airflow in the breathing zone. It supports more efficient oxygen uptake through both nasal and oral pathways while improving patient comfort.

White Paper Abbildung

Figure 1: NasalOxy® low-flow oxygen interface with prongless oxygen delivery design

The NasalOxy® interface is designed to deliver low-flow oxygen through a diffuse, non-intranasal oxygen distribution system positioned below the nostrils. In contrast to conventional nasal cannulas, the design does not require intranasal prongs, thereby minimizing direct contact with the nasal mucosa. The interface is intended to support both nasal and mouth breathing while improving comfort during prolonged oxygen therapy and daily activities.

CLINICAL CHALLENGES IN STANDARD OXYGEN DELIVERY SYSTEMS

The clinical limitations of traditional oxygen delivery systems exte and beyond patient comfort and directly
affect treatment stability. Oxygen delivery through nasal prongs is inherently restricted to the nasal
airway, reducing effectiveness in patients who rely partially or predominantly on oral breathing.

Furthermore, during routine activities such as speaking or eating, the effectiveness of oxygen delivery via
standard nasal cannulas may be educed due to increased mouth breathing and variable inspiratory
patterns.

From a clinical perspective, these challenges can be summarized as:
  • Route limitation: oxygen delivery remains ineffective in patients who predominantly breathe through the mouth
  • Intermittent delivery: oxygen intake is disrupted during everyday activities, reducing consistency of therapy
  • Interface-related discomfort: The use of standard nasal cannulas may result in mucosal drying, irritation, and inflammation of the nasal passages, occasionally leading to epistaxis and localized pain.
NASALOXY® TECHNOLOGY: A PARADIGM SHIFT IN OXYGEN DELIVERY

NasalOxy® introduces a fundamentally different approach based on oxygen distribution within the breathing zone rather than direct intranasal insufflation. The device is externally positioned
between the nose and mouth and utilizes a patented oxygen distributor with a swirler-based mechanism [6]. This system creates a stable, oxygen-enriched airflow that can be inhaled through both nasal and oral
pathways simultaneously.

White Paper Abbildung

Figure 2: Illustration of the NasalOxy® oxygen distribution concept

NasalOxy® generates a gentle, diffuse oxygen flow around the nose and mouth to support low-flow oxygen therapy without intranasal prongs.

Key design features include:
  • Prong-free interface positioned on the upper lip
  • Swirler mechanism for controlled oxygen dispersion
  • Formation of a localized “oxygen cloud”
  • Multi-axis joint for anatomical adaptability
MECHANISM OF ACTION: IMPROVING OXYGENATION EFFICIENCY

The device generates a localized oxygen-rich airflow, increasing the partial pressure of oxygen in the breathing zone and improving diffusion efficiency. Unlike traditional cannulas, this method enhances consistency of delivery. This design reflects a shift from anatomy-dependent delivery toward breathingcentered oxygen therapy, building upon earlier concepts of simultaneous mouth and nose breathing [5].

Three mechanisms underpin its performance:
  • Oxygen cloud formation, enhancing local oxygen availability
  • Dual airway delivery, enabling both nasal and oral breathing
  • Reduced mucosal interaction, minimizing irritation and dryness
White Paper Abbildung

Figure 3: Effect of NasalOxy® on arterial blood gas pO₂ during low-flow oxygen therapy

Comparative evaluations demonstrated higher mean arterial pO₂ values with NasalOxy® compared with conventional nasal cannulas at oxygen flow rates of 2 LPM and 5 LPM. Bars represent mean ± SD after 20 minutes of oxygen administration.

CLINICAL EVIDENCE

In a controlled clinical evaluation in patients with respiratory insufficiency, NasalOxy® was associated with significant improvements in arterial oxygenation parameters at standard low-flow settings. Increases in PaO₂ of approximately 28% at 2 L/min and 71% at 5 L/min were observed, alongside significant improvements in SpO₂ (p < 0.01) [7 and Fig. 3].

White Paper Abbildung

Figure 4. Comparison of NasalOxy® and conventional nasal cannulas during low-flow oxygen therapy

NasalOxy® is a prongless oxygen delivery interface designed to support oxygen administration during both nasal and mouth breathing while reducing direct contact with the nasal mucosa. Compared with conventional nasal cannulas, NasalOxy® may improve patient comfort, reduce mucosal irritation, and support more stable oxygen delivery during low-flow oxygen therapy.

PATIENT EXPERIENCE AND REALWORLD OUTCOMES

By supporting more stable oxygen delivery during routine activities such as speaking and eating, NasalOxy® may help reduce fluctuations in oxygenation and improve overall therapy consistency.
Real-world user feedback indicates that NasalOxy® improves usability and comfort compared to conventional nasal cannulas. Reported benefits include reduced nasal irritation and dryness, improved sleep quality, and more stable oxygen levels during daily activities.

White Paper Abbildung

Figure 5. Patient-centered use of NasalOxy® during long-term low-flow oxygen therapy

Illustration of a patient using the NasalOxy® prong-free oxygen interface. Real-world user feedback indicates improved comfort and tolerance during prolonged oxygen therapy, including reduced nasal dryness and irritation commonly associated with conventional intranasal cannulas. Users also frequently report improved comfort during sleep and daily activities. The interface is designed to support both nasal and oral breathing while minimizing direct mucosal contact.

IMPLEMENTATION CONSIDERATIONS IN CLINICAL AND HOME-CARE SETTINGS
PATIENT SELECTION CONSIDERATIONS

NasalOxy® may be considered for patients requiring low-flow oxygen therapy (1–6 L/min) who experience discomfort or intolerance with conventional nasal cannulas, exhibit mixed nasal/oral breathing patterns, or seek improved comfort during long-term oxygen therapy.

Final patient selection and clinical decision-making remain the responsibility of the treating healthcare professional.

INTEGRATION INTO CARE PATHWAYS

NasalOxy® can be positioned as a comfortable alternative within long-term oxygen therapy programs and a practical solution for both clinical and home-care settings. The device integrates without altering oxygen source, flow settings, or established monitoring protocols. Modern oxygen therapy guidelines emphasize individualized treatment, continuous monitoring, and appropriate selection of delivery systems [3,4].

TRAINING AND ADOPTION CONSIDERATIONS
  • Minimal training required due to intuitive, prong-free design
  • No complex setup or calibration
  • Supports immediate patient acceptance and autonomy
REDEFINING PATIENT-CENTERED OXYGEN THERAPY

NasalOxy® is designed to support more comfortable and adaptive low-flow oxygen therapy by combining clinically relevant oxygen delivery with a prong-free patient-centered interface.

By addressing the practical limitations of conventional nasal cannulas, NasalOxy® aims to improve long-term usability, comfort, and therapy acceptance across clinical and home-care settings.

For clinical inquiries, distribution opportunities, or product information, please contact CNSAC.

TAKE-AWAY BOX
  • Conventional nasal cannulas are associated with oxygen dilution, mucosal irritation, and limited effectiveness during oral breathing
  • NasalOxy® creates a localized oxygen-enriched airflow in the breathing zone, supporting both nasal and oral inhalation
  • Clinical evaluation showed significant improvements in PaO₂ (28% at 2 L/min, 71% at 5 L/min) and SpO₂
  • The prong-free design markedly improves patient comfort and tolerance
  • NasalOxy® offers a patient-centered, next-generation solution for low-flow oxygen therapy
REFERENCES
  1. 1. Koczulla AR, Schneeberger T, Jarosch I, Kenn K, Gloeckl R. Long-term oxygen therapy. Dtsch Arztebl Int.
    2018;115(51-52):871-877. doi:10.3238/arztebl.2018.0871

  2. 2. Sharma S, Danckers M, Sanghavi DK, Chakraborty RK. High-flow nasal cannula. StatPearls [Internet]. Treasure
    Island (FL): StatPearls Publishing; 2026. PMID:30252327

  3. 3. O‘Driscoll BR, Howard LS, Earis J, Mak V; British Thoracic Society Emergency Oxygen Guideline Group; BTS
    Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and
    emergency settings. Thorax. 2017;72(Suppl 1):ii1-ii90. doi:10.1136/thoraxjnl-2016-209729

  4. 4. Barnett A, Beasley R, Buchan C, Chien J, Farah CS, King G, et al. Thoracic Society of Australia and New Zealand
    position statement on acute oxygen use in adults: “Swimming between the flags”. Respirology. 2022;27:262-
    276. doi:10.1111/resp.14218

  5. 5. Köhler D, Knoch M, Sommerfeld C, Müller H. A new oxygen applicator for simultaneous mouth and nose
    breathing. Chest. 1993;103(4):1157-1160. doi:10.1378/chest.103.4.1157

  6. 6. Köhler D, Löwenstein R. Oxygen distributor for use in oxygen inhalation therapy. European Patent EP2578262B1.
    European Patent Office; 2017.

  7. 7. Kianian A, Ghafoori T, Abu Hassan O. A new low-flow oxygen cannula provides advanced oxygen delivery by
    allowing simultaneous oral and nasal breathing. CNSAC Internal Study. Published 2024. Accessed May 14, 2026.
    https://www.cnsac-medshop.com/en/blogs/unkategorisiert/low-flow-oxygen-cannulanasaloxy

Suchen Sie auf unserer Seite